If you have a high tolerance for risk, then it could be worth checking out Vitrafy Life Sciences Ltd (ASX: VFY).
That's the view of analysts at Bell Potter, which believe the speculative ASX stock could generate big returns over the next 12 months.
What is Vitrafy?
Vitrafy is aiming to become a global leader in cryopreservation by significantly improving cell survival of biological materials.
It has designed and developed an innovative solution for the advancement of cryopreservation, which includes smart devices, a quality management software platform, and smart packaging solutions.
Bell Potter notes that Vitrafy's technology is free of expensive and complex liquid nitrogen processes and is at the beginning of its commercialisation phase. It feels that it has the potential to be a significant disrupter in the field of freezing and thawing biological materials, with a significant range of possible applications.
What is the broker saying about this speculative ASX stock?
Bell Potter highlights that this speculative ASX stock has significant total addressable markets (TAM) that offer exposure to three broad global market themes.
It notes that Aquaculture & Bovine reproduction has a TAM of ~US$3.7 billion, while Blood Platelets is at ~US$5.7 billion, and Human Cell & Gene Therapy is at ~US$5.5 billion.
Bell Potter also points out that the company has collaboration partnerships with brand name operators in each market, that could each generate material revenue, if converted to full commercial partners.
Big return potential
In light of the above, the broker has initiated coverage on the cryopreservation company's shares with a speculative buy rating and $2.36 price target.
Based on its current share price of $1.69, this implies potential upside of approximately 40% for investors over the next 12 months.
Commenting on its (speculative) buy recommendation, the broker said:
As VFY develops, we expect its financial profile to reflect a high volume and sticky customer base that generates modest gross margins, but a capital light model and a relatively lean cost base should still deliver solid EBITDA margins / ROC over the medium-to-long term.
Bell Potter also named a number of catalysts that could drive this ASX stock higher. It concludes:
Key catalysts include 1) securing commercial partners in animal reproduction, blood platelets and cell and gene therapy, 2) demonstrating a capacity to expedite the customer contracting process, and 3) FDA approval of the 2nd generation device VCU2 in 2HCY26 to enable pursuit of the regulated human health market.
